In the latest close session, Moderna (MRNA) was down 3.45% at $42.55. The stock's change was less than the S&P 500's daily gain of 0.54%. At the same time, the Dow added 1.05%, and the tech-heavy ...

Moderna, Inc. (NASDAQ:MRNA) is one of the noteworthy S&P 500 stocks Jim Cramer highlighted. Cramer highlighted that the ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving from 1.90% in May to 1.96%, indicating a collective rise in negative bets ...

Moderna rises after five-year phase IIb data show the combo of intismeran autogene plus Keytruda cuts recurrence or death risk by 49% in high-risk melanoma.

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...